CoChat
Sign Up
Cited by 41Psoriasis: Treatment and PathogenesisDermatology and Skin DiseasesSpondyloarthritis Studies and Treatments

Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients

Open access
Wan, Joy, Abuabara, Katrina, Troxel, Andrea B., Shin, Daniel B., Van Voorhees, Abby S., Bebo, Bruce F., Krueger, Gerald G., Callis Duffin, Kristina +1 more·2012·Journal of the American Academy of Dermatology
DOI 10.1016/j.jaad.2011.03.012PMC PMC3223538
Open this paper in CoChat — free account

Abstract

Background Despite increasing therapies for moderate to severe psoriasis, dermatologists' treatment preferences are unknown. Objective We sought to assess dermatologists' preferences for first-line treatments and their selection determinants. Methods We surveyed 1000 US dermatologists (500 National Psoriasis Foundation and 500 American Academy of Dermatology members who treat psoriasis) about their preferences for first-line treatment of moderate to severe psoriasis in healthy adults of childbearing age using standardized patient vignettes. Results The response rate was 39% (N = 387). Preferred therapies for male and female patients were: ultraviolet (UV) B (40% and 56%, respectively), etanercept (15% and 19%), methotrexate (16% and 4%), and adalimumab (12% and 10%). Of respondents, 66% administered phototherapy in their practice. After adjusting for all physician characteristics, those preferring first-line UVB for male or female patients were significantly more likely to have phototherapy in their practice (odds ratio [OR] 3.4, 95% confidence interval [CI] 1.8-6.6 and OR 2.8, 95% CI 1.5-5.3, respectively) and to have used UVB in more than 10 patients in the last 3 months (OR 8.0, 95% CI 3.9-16.4; OR 9.6, 95% CI 4.3-21.6). Dermatologists in the Midwest were more likely than those in the Northeast to prefer adalimumab first line for male and female patients. Limitations We surveyed only dermatologists with interest in treating psoriasis and elicited their treatment preferences for a single base case scenario. Treatment preferences may differ between survey respondents and nonrespondents. Conclusion UVB is most commonly preferred as a first-line treatment for moderate to severe psoriasis in healthy adults, and preferences vary based on region, phototherapy availability, and prior treatment use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2011.03.012

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • UVA1 induces cyclobutane pyrimidine dimers but not 6-4 photoproducts in human skin in vivo.

    “UVA1 induces cyclobutane pyrimidine dimers but not 6–4 photoproducts in human skin in vivo[109].”

    From Molecular Mechanisms of UV-Induced Apoptosis and Its Effects on Skin Residential Cells: The Implication in UV-Based Phototherapy (2013) · cites this paper as [109]

    The Results and Discussion (page unavailable) concern dermatologists’ preferences for psoriasis treatments, particularly UVB phototherapy. Searches for UVA1, cyclobutane pyrimidine dimers, and 6–4 photoproducts found no passage addressing DNA lesions in human skin. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. [1]Stern RS Nijsten T Feldman SR Margolis DJ Rolstad T Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction J Investig Dermatol Symp Proc 2004 9 136 139 15083780
  2. [2]Kurd SK Gelfand JM The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004 J Am Acad Dermatol 2009 60 218 224 19022533 PMC4762027
  3. [3]Griffiths CE Barker JN Pathogenesis and clinical features of psoriasis Lancet 2007 370 263 271 17658397
  4. [5]Gelfand JM Troxel AB Lewis JD Kurd SK Shin DB Wang X The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 2007 143 1493 1499 18086997
  5. [6]Abuabara K Azfar RS Shin DB Neimann AL Troxel AB Gelfand JM Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K Br J Dermatol 2010 163 586 592 20633008 PMC2966545
  6. [7]Chaudhari U Romano P Mulcahy LD Dooley LT Baker DG Gottlieb AB Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Lancet 2001 357 1842 1847 11410193
  7. [8]Ellis CN Krueger GG Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 2001 345 248 255 11474662
  8. [9]Leonardi CL Powers JL Matheson RT Goffe BS Zitnik R Wang A Etanercept as monotherapy in patients with psoriasis N Engl J Med 2003 349 2014 2022 14627786
  9. [10]Leonardi CL Kimball AB Papp KA Yeilding N Guzzo C Wang Y Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 2008 371 1665 1674 18486739
  10. [11]Menter A Tyring SK Gordon K Kimball AB Leonardi CL Langley RG Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial J Am Acad Dermatol 2008 58 106 115 17936411
  11. [12]Menter A Gottlieb A Feldman SR Van Voorhees AS Leonardi CL Gordon KB Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 2008 58 826 850 18423260
  12. [13]Menter A Korman NJ Elmets CA Feldman SR Gelfand JM Gordon KB Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents J Am Acad Dermatol 2009 61 451 485 19493586
  13. [14]Menter A Korman NJ Elmets CA Feldman SR Gelfand JM Gordon KB Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy J Am Acad Dermatol 2010 62 114 135 19811850
  14. [15]Pathirana D Ormerod AD Saiag P Smith C Spuls PI Nast A European S3-guidelines on the systemic treatment of psoriasis vulgaris J Eur Acad Dermatol Venereol 2009 23 Suppl 2 1 70 19712190
  15. [17]Smith CH Anstey AV Barker JN Burden AD Chalmers RJ Chandler D British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 Br J Dermatol 2005 153 486 497 16120132
  16. [18]Nast A Kopp IB Augustin M Banditt KB Boehncke WH Follmann M Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris J Dtsch Dermatol Ges 2007 5 Suppl 3 1 119 17615051
  17. [19]Institute of Medicine Initial national priorities for comparative effectiveness research 2009 Washington, DC The National Academies Press
  18. [20]Peabody JW Luck J Glassman P Dresselhaus TR Lee M Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality JAMA 2000 283 1715 1722 10755498
  19. [21]Peabody JW Luck J Glassman P Jain S Hansen J Spell M Measuring the quality of physician practice by using clinical vignettes: a prospective validation study Ann Intern Med 2004 141 771 780 15545677
  20. [22]Veloski J Tai S Evans AS Nash DB Clinical vignette-based surveys: a tool for assessing physician practice variation Am J Med Qual 2005 20 151 157 15951521
  21. [23]Dillman DA Mail and telephone surveys: the total design method 1978 New York Wiley
  22. [24]Dillman DA Mail and Internet surveys: the tailored design method 2000 New York J. Wiley
  23. [25]Wan J Abuabara K Shin DB Troxel AB Bebo BF Jr Gelfand JM Dermatologist response rates to a mailed questionnaire: a randomized trial of monetary incentives Submitted for review PMC3242906 22036576
  24. [27]Housman TS Rohrback JM Fleischer AB Jr Feldman SR Phototherapy utilization for psoriasis is declining in the United States J Am Acad Dermatol 2002 46 557 559 11907508
  25. [28]Simpson GL Yelverton CB Rittenberg S Feldman SR Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat 2006 17 359 361 17853310
  26. [29]Sariego J Regional variation in breast cancer treatment throughout the United States Am J Surg 2008 196 572 574 18809065
  27. [30]Krumholz HM Chen J Rathore SS Wang Y Radford MJ Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage Am Heart J 2003 146 242 249 12891191
  28. [31]Dommasch ED Abuabara K Shin DB Nguyen J Troxel AB Gelfand JM The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials Journal of the American Academy of Dermatology In press PMC3095673 21315483
  29. [32]Schmitt J Zhang Z Wozel G Meurer M Kirch W Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials Br J Dermatol 2008 159 513 526 18627372
  30. [33]Perneger TV What's wrong with Bonferroni adjustments BMJ 1998 316 1236 1238 9553006 PMC1112991
  31. [34]Savitz DA Olshan AF Describing data requires no adjustment for multiple comparisons: a reply from Savitz and Olshan Am J Epidemiol 1998 147 813 814 9583710
  32. [35]Flytstrom I Stenberg B Svensson A Bergbrant IM Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial Br J Dermatol 2008 158 116 121 17986302
  33. [36]Griffiths CE Strober BE van de Kerkhof P Ho V Fidelus-Gort R Yeilding N Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 2010 362 118 128 20071701
  34. [37]Heydendael VM Spuls PI Opmeer BC de Borgie CA Reitsma JB Goldschmidt WF Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 2003 349 658 665 12917302
  35. [38]Saurat JH Stingl G Dubertret L Papp K Langley RG Ortonne JP Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol 2008 158 558 566 18047523

Cited by

Sorted by citations

Authors
Wan, J., Abuabara, K., Troxel, A. B., Shin, D. B., Van Voorhees, A. S., Bebo, B. F., Krueger, G. G., Callis Duffin, K., & Gelfand, J. M.
Affiliations
  • University of Pennsylvania (US)
  • National Psoriasis Foundation (US)
  • University of Utah (US)
Corresponding author
Gelfand, Joel M.
ORCID
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2012-03
Volume
66
Issue
3
Pages
376-386
ISSN
0190-9622 (ISSN-L)
DOI
10.1016/j.jaad.2011.03.012
PMC
PMC3223538
OpenAlex
W2027849587
Cited by
41
References
2
Citations by year
2025: 3 · 2024: 1 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 3 · 2013: 6 · 2012: 3
FWCI
1.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American Academy of Dermatology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR07465, RC1AR058204, T32AR007465)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
Keywords
psoriasis, first-line therapy, UVB phototherapy, etanercept, methotrexate, adalimumab, patient vignettes
MeSH terms
Etanercept, Adalimumab, Adult, Attitude of Health Personnel, Dermatology, Female, Humans, Immunoglobulin G, Immunosuppressive Agents, Male, Methotrexate, Professional Practice, Psoriasis, Severity of Illness Index, Ultraviolet Therapy, Receptors, Tumor Necrosis Factor, Health Care Surveys, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review